We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




POC Bladder Cancer Test as Accurate as Lab Test

By HospiMedica staff writers
Posted on 04 Dec 2001
A new point-of-care (POC) test for bladder cancer has been shown to be as accurate as a laboratory-based test, according to a study presented at Perspectives in Bladder Cancer, a conference of the European Organization for Research and Treatment of Cancer (Monte Carol, Monaco).

The study compared results of the POC test to the results of a microplate format test in analyzing urine from 196 patients at urology clinics. More...
The overall concordance between the two assays was 95%. The microplate format test identified 16 samples as positive, while the POC test identified 15 as positive; and the microplate test detected 171 negative samples, while the POC test identified 163. Both tests detect nuclear matrix protein (NMP) found in the nucleus of cells. NMP is elevated in bladder cancer patients by 10-100 times and is released into the urine of bladder cancer patients. The BladderChek test is to be used in conjunction with cystoscopy.

Both the POC test and the microplate test, which has been cleared by the U.S. Food and Drug Administration (FDA), are the products of Matritech, Inc. (Newton, MA, USA). NMP tests have been found in other studies to be twice as sensitive as cytology in detecting low-grade tumors. The POC test can produce results while the patient is in a doctor's office, whereas lab tests can take two to three days to deliver results.




Related Links:
Matritech

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.